Steroids: Pharmacology, Complications, and Practice Delivery Issues

REFERENCES

1. ↵
   1. Kendall EC

   (1950) Nobel lecture: The development of cortisone as a therapeutic agent. Nobelprize.org, December 11, http://www.nobelprize.org/nobel_prizes/medicine/laureates/1950/kendall-lecture.html. Accessed March 10, 2013.
2. ↵
   1. Melmed S,
   2. Polonsky K,
   3. Larsen PR,
   4. Kronenberg H

   1. Stewart PM,
   2. Krone NP

   (2011) in Williams Textbook of Endocrinology. 12^th ed, The adrenal cortex, eds Melmed S, Polonsky K, Larsen PR, Kronenberg H (Saunders; Philadelphia, PA) In, eds.
3. ↵
   1. Xu J,
   2. Winkler J,
   3. Derendorf H

   (6, 2007) A pharmacokinetic/pharmacodynamic approach to predict total prednisolone concentrations in human plasma. J Pharmacokinet Pharmacodyn 34(3):355–372, pmid:17318442, Epub 2007 Feb 23.

   OpenUrlCrossRefPubMed
4. ↵
   1. Curtis JR,
   2. Westfall AO,
   3. Allison J,
   4. et al.

   (6 15, 2006) Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 55(3):420–426, pmid:16739208.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   1. Kenna HA,
   2. Poon AW,
   3. de los Angeles CP,
   4. Koran LM

   (10, 2011) Psychiatric complications of treatment with corticosteroids: review with case report. Psychiatry Clin Neurosci 65(6):549–560, pmid:22003987.

   OpenUrlCrossRefPubMedWeb of Science
6. 1. Warrington TP,
   2. Bostwick JM

   (10, 2006) Psychiatric adverse effects of corticosteroids. Mayo Clin Proc 81(10):1361–1367, pmid:17036562.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. Patten SB,
   2. Neutel CI

   (2, 2000) Corticosteroid-induced adverse psychiatric effects: incidence, diagnosis and management. Drug Saf 22(2):111–122, pmid:10672894.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   1. Pereira RM,
   2. Carvalho JF,
   3. Canalis E

   (2010) Glucocorticoid-induced osteoporosis in rheumatic diseases. Clinics (Sao Paulo) 65(11):1197–1205, pmid:21243296.

   OpenUrlPubMed
9. ↵
   1. Lansang MC,
   2. Hustak LK

   (11, 2011) Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them. Cleve Clin J Med 78(11):748–756, pmid:22049542.

   OpenUrlAbstract/FREE Full Text
10. ↵
    1. Benzon HT,
    2. Gissen AJ,
    3. Strichartz GR,
    4. Avram MJ,
    5. Covino BG

    (6, 1987) The effect of polyethylene glycol on mammalian nerve impulses. Anesth Analg 66(6):553–559, pmid:3578866.

    OpenUrlPubMedWeb of Science
11. ↵
    1. Craig DB,
    2. Habib GG

    (Mar-Apr 1977) Flaccid paraparesis following obstetrical epidural anesthesia: possible role of benzyl alcohol. Anesth Analg 56(2):219–221, pmid:557917.

    OpenUrlPubMedWeb of Science
12. ↵
    1. Ahadian FM,
    2. McGreevy K,
    3. Schulteis G

    (Nov-Dec 2011) Lumbar transforaminal epidural dexamethasone: a prospective, randomized, double-blind, dose-response trial. Reg Anesth Pain Med 36(6):572–578, pmid:22005659.

    OpenUrlCrossRefPubMed
13. ↵
    1. Dreyfuss P,
    2. Baker R,
    3. Bogduk N

    (May-Jun 2006) Comparative effectiveness of cervical transforaminal injections with particulate and nonparticulate corticosteroid preparations for cervical radicular pain. Pain Med 7(3):237–242, pmid:16712623.

    OpenUrlCrossRefPubMed
14. ↵
    1. Somayaji HS,
    2. Saifuddin A,
    3. Casey AT,
    4. Briggs TW

    (2 15, 2005) Spinal cord infarction following therapeutic computed tomography-guided left L2 nerve root injection. Spine (Phila Pa 1976) 30(4):E106–E108, pmid:15706327.

    OpenUrlCrossRefPubMed
15. ↵
    1. McClain RW,
    2. Yentzer BA,
    3. Feldman SR

    (12, 2009) Comparison of skin concentrations following topical versus oral corticosteroid treatment: reconsidering the treatment of common inflammatory dermatoses. J Drugs Dermatol 8(12):1076–1079, pmid:20027934.

    OpenUrlPubMed
16. ↵
    1. Morley KW,
    2. Dinulos JG

    (2, 2012) Update on topical glucocorticoid use in children. Curr Opin Pediatr 24(1):121–128, pmid:22227781.

    OpenUrlCrossRefPubMed
17. ↵
    1. Busse WW,
    2. Bleecker ER,
    3. Bateman ED,
    4. et al.

    (1, 2012) Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax 67(1):35–41, pmid:21828231, Epub 2011 Aug 9.

    OpenUrlAbstract/FREE Full Text
18. ↵
    1. Doherty DE,
    2. Tashkin DP,
    3. Kerwin E,
    4. et al.

    Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD. Int J Chron Obstruct Pulmon Dis. 2012; 7:57–71, Epub 2012 Feb 3.
19. ↵
    1. Taplin CE,
    2. Cowell CT,
    3. Silink M,
    4. Ambler GR

    (12, 2006) Fludrocortisone therapy in cerebral salt wasting. Pediatrics 118(6):e1904–e1908, pmid:17101713.

    OpenUrlAbstract/FREE Full Text
20. 1. Freitas J,
    2. Santos R,
    3. Azevedo E,
    4. Costa O,
    5. Carvalho M,
    6. de Freitas AF

    (10, 2000) Clinical improvement in patients with orthostatic intolerance after treatment with bisoprolol and fludrocortisone. Clin Auton Res 10(5):293–299, pmid:11198485.

    OpenUrlCrossRefPubMedWeb of Science
21. ↵
    1. Physicians Total Care, Inc

    (2010) Fludrocortisone acetate tablet. Daily Med, September, http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bf927cd9-1891-4de4-b4be-743a26363a64. Accessed April 1, 2014.
22. ↵
    1. Wallner BP,
    2. Mattaliano RJ,
    3. Hession C,
    4. et al.

    (3 6-12, 1986) Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity. Nature 320(6057):77–81, pmid:2936963.

    OpenUrlCrossRefPubMed
23. ↵
    1. Rhen T,
    2. Cidlowski JA

    (10 20, 2005) Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med 353(16):1711–1723, pmid:16236742.

    OpenUrlCrossRefPubMedWeb of Science
24. ↵
    1. Blackwell GJ,
    2. Carnuccio R,
    3. Di Rosa M,
    4. Flower RJ,
    5. Parente L,
    6. Persico P

    (9 11, 1980) Macrocortin: a polypeptide causing the anti-phospholipase effect of glucocorticoids. Nature 287(5778):147–149, pmid:6893620.

    OpenUrlCrossRefPubMedWeb of Science
25. ↵
    1. Cooper MS,
    2. Stewart PM

    (2 20, 2003) Corticosteroid insufficiency in acutely ill patients. N Engl J Med 348(8):727–734, pmid:12594318.

    OpenUrlCrossRefPubMedWeb of Science
26. ↵
    1. Centers for Disease Control and Prevention

    (2013) Multistate outbreak of fungal meningitis and other infections. Centers for Disease Control and Prevention, October 23, http://www.cdc.gov/hai/outbreaks/meningitis.html. Accessed April 1, 2014.
27. ↵
    1. US Food and Drug Administration

    (2010) 2006 Limited Survey of Compounded Drug Products, March 22, http://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/pharmacycompounding/ucm204237.htm. Accessed March 14, 2013.
28. ↵
    1. US Food and Drug Administration

    (2012) FDA Form 483: inspectional observations. http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofGlobalRegulatoryOperationsandPolicy/ORA/ORAElectronicReadingRoom/UCM325980.pdf. Accessed March 14, 2013.
29. ↵
    1. US Food and Drug Administration

    (2014) Compounding Quality Act, Title I of the Drug Quality and Security Act of 2013, January 10, http://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/pharmacycompounding/default.htm. Accessed April 1, 2014.